Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2024 08:00 ET | Source: Tr1X Bio

Tr1X to Participate at Upcoming Healthcare Investment Conferences

SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company specializing in allogeneic engineered Treg and CAR-Treg cell therapies with the potential to...
August 07, 2024 08:00 ET | Source: Tr1X Bio

Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company specializing in allogeneic engineered Treg and CAR-Treg cell therapies with the potential to...
July 10, 2024 08:00 ET | Source: Tr1X Bio

Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

This marks the first use of an allogeneic engineered Type 1 Treg (Tr1) cell therapy in clinical trials. The first patient has successfully cleared the safety period with no serious adverse events. ...